Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Effects of thiazolidinediones on bone loss and fracture.

Murphy CE, Rodgers PT.

Ann Pharmacother. 2007 Dec;41(12):2014-8. Epub 2007 Oct 16. Review.

PMID:
17940125
2.

The effect of thiazolidinediones on BMD and osteoporosis.

McDonough AK, Rosenthal RS, Cao X, Saag KG.

Nat Clin Pract Endocrinol Metab. 2008 Sep;4(9):507-13. doi: 10.1038/ncpendmet0920. Review. Erratum in: Nat Clin Pract Endocrinol Metab. 2008 Nov;4(11):643.

PMID:
18695700
3.

Bone health in diabetes: considerations for clinical management.

Adami S.

Curr Med Res Opin. 2009 May;25(5):1057-72. doi: 10.1185/03007990902801147 . Review.

PMID:
19292601
4.

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial.

Gruntmanis U, Fordan S, Ghayee HK, Abdullah SM, See R, Ayers CR, McGuire DK.

Calcif Tissue Int. 2010 May;86(5):343-9. doi: 10.1007/s00223-010-9352-5. Epub 2010 Mar 31.

PMID:
20354684
5.

The effect of thiazolidinediones on bone mineral density in Chinese older patients with type 2 diabetes.

Li H, Cui R, Cai H, Wu G, Lv Z, Sheng C, Cheng X, Li F, Yu Y.

J Bone Miner Metab. 2010;28(1):77-81. doi: 10.1007/s00774-009-0104-4. Epub 2009 Jul 16.

PMID:
19603247
6.

Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis.

Sorocéanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC.

J Endocrinol. 2004 Oct;183(1):203-16.

7.

Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study.

Berberoglu Z, Yazici AC, Demirag NG.

Clin Endocrinol (Oxf). 2010 Sep;73(3):305-12. doi: 10.1111/j.1365-2265.2010.03784.x. Epub 2010 Feb 10.

PMID:
20148906
8.

[Thiazolidinediones and skeletal health].

Meier C, Bodmer M, Meier CR, Kraenzlin ME.

Rev Med Suisse. 2009 Jun 10;5(207):1309-10, 1312-3. Review. French.

PMID:
19626930
9.

Thiazolidinediones and fractures in men and women.

Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM.

Arch Intern Med. 2009 Aug 10;169(15):1395-402. doi: 10.1001/archinternmed.2009.214.

PMID:
19667303
10.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
11.

Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.

Koufany M, Moulin D, Bianchi A, Muresan M, Sebillaud S, Netter P, Weryha G, Jouzeau JY.

Arthritis Res Ther. 2008;10(1):R6. doi: 10.1186/ar2354. Epub 2008 Jan 16.

12.

Effect of thiazolidinediones on skeletal health in women with Type 2 diabetes.

Schwartz AV, Sellmeyer DE.

Expert Opin Drug Saf. 2008 Jan;7(1):69-78. doi: 10.1517/14740338.7.1.69 . Review.

PMID:
18171315
13.

Thiazolidinedione-induced skeletal fragility--mechanisms and implications.

Grey A.

Diabetes Obes Metab. 2009 Apr;11(4):275-84. doi: 10.1111/j.1463-1326.2008.00931.x. Epub 2008 Jul 29. Review.

PMID:
18671797
14.

Use of thiazolidinediones and fracture risk.

Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR.

Arch Intern Med. 2008 Apr 28;168(8):820-5. doi: 10.1001/archinte.168.8.820.

PMID:
18443256
15.

How safe is the use of thiazolidinediones in clinical practice?

Rizos CV, Elisaf MS, Mikhailidis DP, Liberopoulos EN.

Expert Opin Drug Saf. 2009 Jan;8(1):15-32. doi: 10.1517/14740330802597821 . Review.

PMID:
19236215
16.

Vitamin A intake and osteoporosis: a clinical review.

Crandall C.

J Womens Health (Larchmt). 2004 Oct;13(8):939-53. Review.

PMID:
15671709
17.

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G; Diabetes Outcome Progression Trial (ADOPT) Study Group.

Diabetes Care. 2008 May;31(5):845-51. doi: 10.2337/dc07-2270. Epub 2008 Jan 25.

PMID:
18223031
18.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
19.

[Daily practice using the guidelines for prevention and treatment of osteoporosis. Anti-diabetic agents and fracture risk].

Okazaki R.

Clin Calcium. 2008 Aug;18(8):1154-61. doi: CliCa080811541161. Review. Japanese.

PMID:
18677054
20.

Bone metabolism in type 2 diabetes and role of thiazolidinediones.

Vestergaard P.

Curr Opin Endocrinol Diabetes Obes. 2009 Apr;16(2):125-31. doi: 10.1097/MED.0b013e328325d155. Review.

PMID:
19300092

Supplemental Content

Support Center